TY - JOUR
T1 - Abundant HIV-infected cells in blood and tissues are rapidly cleared upon ART initiation during acute HIV infection
AU - Leyre, Louise
AU - Kroon, Eugène
AU - Vandergeeten, Claire
AU - Sacdalan, Carlo
AU - Colby, Donn J.
AU - Buranapraditkun, Supranee
AU - Schuetz, Alexandra
AU - Chomchey, Nitiya
AU - De Souza, Mark
AU - Bakeman, Wendy
AU - Fromentin, Rémi
AU - Pinyakorn, Suteeraporn
AU - Akapirat, Siriwat
AU - Trichavaroj, Rapee
AU - Chottanapund, Suthat
AU - Manasnayakorn, Sopark
AU - Rerknimitr, Rungsun
AU - Wattanaboonyoungcharoen, Phandee
AU - Kim, Jerome H.
AU - Tovanabutra, Sodsai
AU - Schacker, Timothy W.
AU - O'Connell, Robert
AU - Valcour, Victor G.
AU - Phanuphak, Praphan
AU - Robb, Merlin L.
AU - Michael, Nelson
AU - Trautmann, Lydie
AU - Phanuphak, Nittaya
AU - Ananworanich, Jintanat
AU - Chomont, Nicolas
N1 - Publisher Copyright:
© 2020 The Authors.
PY - 2020/3/4
Y1 - 2020/3/4
N2 - The timing and location of the establishment of the viral reservoir during acute HIV infection remain unclear. Using longitudinal blood and tissue samples obtained from HIV-infected individuals at the earliest stage of infection, we demonstrate that frequencies of infected cells reach maximal values in gut-associated lymphoid tissue and lymph nodes as early as Fiebig stage II, before seroconversion. Both tissues displayed higher frequencies of infected cells than blood until Fiebig stage III, after which infected cells were equally distributed in all compartments examined. Initiation of antiretroviral therapy (ART) at Fiebig stages I to III led to a profound decrease in the frequency of infected cells to nearly undetectable level in all compartments. The rare infected cells that persisted were preferentially found in the lymphoid tissues. Initiation of ART at later stages (Fiebig stages IV/V and chronic infection) induced only a modest reduction in the frequency of infected cells. Quantification of HIV DNA in memory CD4+ T cell subsets confirmed the unstable nature of most of the infected cells at Fiebig stages I to III and the emergence of persistently infected cells during the transition to Fiebig stage IV. Our results indicate that although a large pool of cells is infected during acute HIV infection, most of these early targets are rapidly cleared upon ART initiation. Therefore, infected cells present after peak viremia have a greater ability to persist.
AB - The timing and location of the establishment of the viral reservoir during acute HIV infection remain unclear. Using longitudinal blood and tissue samples obtained from HIV-infected individuals at the earliest stage of infection, we demonstrate that frequencies of infected cells reach maximal values in gut-associated lymphoid tissue and lymph nodes as early as Fiebig stage II, before seroconversion. Both tissues displayed higher frequencies of infected cells than blood until Fiebig stage III, after which infected cells were equally distributed in all compartments examined. Initiation of antiretroviral therapy (ART) at Fiebig stages I to III led to a profound decrease in the frequency of infected cells to nearly undetectable level in all compartments. The rare infected cells that persisted were preferentially found in the lymphoid tissues. Initiation of ART at later stages (Fiebig stages IV/V and chronic infection) induced only a modest reduction in the frequency of infected cells. Quantification of HIV DNA in memory CD4+ T cell subsets confirmed the unstable nature of most of the infected cells at Fiebig stages I to III and the emergence of persistently infected cells during the transition to Fiebig stage IV. Our results indicate that although a large pool of cells is infected during acute HIV infection, most of these early targets are rapidly cleared upon ART initiation. Therefore, infected cells present after peak viremia have a greater ability to persist.
UR - http://www.scopus.com/inward/record.url?scp=85081333117&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.aav3491
DO - 10.1126/scitranslmed.aav3491
M3 - Article
C2 - 32132218
AN - SCOPUS:85081333117
SN - 1946-6234
VL - 12
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 533
M1 - eaav3491
ER -